This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vista Partners Updates Coverage On ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price









SAN FRANCISCO, March 21, 2012 /PRNewswire/ --  Vista Partners announced today that it has updated coverage on ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) ("The Company" or "ANX") ; and maintains its twelve month target price of $3.50. Ross Silver, Principal Analyst at Vista Partners stated, "The GlycoMimetics deal with Pfizer, as reported by theflyonthewall.com, for their investigational compound GMI-1070 currently in Phase 2 development for the treatment of vaso-occlusive crisis associated with sickle cell disease has a potential value of approximately $340M. This deal would seem to provide a benchmark for which to base value of ANX-188, which ADVENTRX has stated, will begin a Phase 3 trial in 2012." Mr. Silver continues "ANX currently trades at a negative enterprise value with its market cap currently being less than its cash balance. In addition, the cash value per share was approximately $1.06 at 2011 year end, a discount of approximately 71% from the current share price. This would seem to indicate that the Company is currently being given little to no value for its two Phase 3 clinical candidates which could serve large markets: ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis; and ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere."



To download a FREE copy of the ADVENTRX Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:877.215.4813 or info@vistapglobal.com

SOURCE Vista Partners

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,180.06 +48.09 0.28%
S&P 500 2,002.72 +3.74 0.19%
NASDAQ 4,559.8470 +7.0880 0.16%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs